Outlook Therapeutics, Inc. (OTLK) stock
OTLKNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends September 30
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Aug 18, 2026Score 4/30
$0.41+0.05 (+13.12%)
Close on Nov 18, 2026Market cap $99.30MP/E –Yield –
Outlook Therapeutics total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Outlook Therapeutics's total debt was $967.06M at Jun 30, 2020. For fiscal 2019 it was $1.08B, up 652426.3% from the year before. The highest annual figure on record is $1.08B in fiscal 2019.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2019 | Sep 30, 2019 | $1.08B | +652426.3% |
| FY2018 | Sep 30, 2018 | $164.97K | -19.0% |
| FY2017 | Sep 30, 2017 | $203.71K | -92.8% |
| FY2016 | Sep 30, 2016 | $2.82M | -23.1% |
| FY2015 | Sep 30, 2015 | $3.67M | – |
Quarterly total debt
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2020CQ2 2020 | Jun 30, 2020 | $967.06M | +673862.3% |
| Q4 FY2019CQ3 2019 | Sep 30, 2019 | $1.08B | +652426.3% |
| Q3 FY2019CQ2 2019 | Jun 30, 2019 | $1.11M | +460.6% |
| Q2 FY2019CQ1 2019 | Mar 31, 2019 | $1.13M | +388.9% |
| Q1 FY2019CQ4 2018 | Dec 31, 2018 | $143.49K | -45.3% |
| Q4 FY2018CQ3 2018 | Sep 30, 2018 | $164.97K | -19.0% |
| Q3 FY2018CQ2 2018 | Jun 30, 2018 | $198.28K | -8.1% |
| Q2 FY2018CQ1 2018 | Mar 31, 2018 | $230.69K | -8.8% |
| Q1 FY2018CQ4 2017 | Dec 31, 2017 | $262.25K | -13.1% |
| Q4 FY2017CQ3 2017 | Sep 30, 2017 | $203.71K | -92.8% |
| Q3 FY2017CQ2 2017 | Jun 30, 2017 | $215.76K | -71.3% |
| Q2 FY2017CQ1 2017 | Mar 31, 2017 | $253.07K | -66.7% |
| Q1 FY2017CQ4 2016 | Dec 31, 2016 | $301.63K | – |
| Q4 FY2016CQ3 2016 | Sep 30, 2016 | $2.82M | – |
| Q3 FY2016CQ2 2016 | Jun 30, 2016 | $752.45K | – |
| Q2 FY2016CQ1 2016 | Mar 31, 2016 | $760.01K | – |
See a number that looks wrong?